Funded by Unitaid, the IMPAACT4TB Consortium works in collaboration with the World Health Organisation(WHO) and focused primarily on providing safer, shorter TPT (3HP and 1HP) that is affordable and accessible to target populations: People living with HIV, children under 5 years and all household contacts.
The IMPAACT4TB Consortium members have exceptional experience in shaping markets, strengthening supply chain management and supporting National TB Programmes in high-burden countries. The consortium has implemented innovative strategies to deliver 3HP and 1HP to high-risk groups in the 12 project countries, and the lessons learned along the way will be used to generate more evidence, support scale-up globally and contribute to meeting the global End TB targets.
The price dropped from $72 in 2017 to $14,25 in 2022.
Increased from 180k patient courses in 2018 to over 4mill in 2022.
12 of 12 Project countries have included 3HP in the National Health Guidelines
From 1(one) country in 2018 to 56 (fifty-six) countries in 2022.
The IMPAACT4TB Project has moved into the next phase to generate more evidence for vulnerable and undeserved populations.
